Tech Company Financing Transactions
Triastek Funding Round
On 9/28/2023, Triastek raised $20.4 million in Series B funding from Shanghai Guoxin, CPE Capital and Dalton Venture.
Transaction Overview
Company Name
Announced On
9/28/2023
Transaction Type
Venture Equity
Amount
$20,400,000
Round
Series B
Investors
Proceeds Purpose
The company will use the funds to Accelerate Commercialization of 3D Printing Pharmaceutical Technology and Products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
24 Building, Max Science Business Park, 99 Lize Road
Nanjing, Jiangsu, Undisclosed
CN
Nanjing, Jiangsu, Undisclosed
CN
Phone
Undisclosed
Website
Email Address
Overview
Triastek is a global healthcare company, developing medicines with proprietary, pioneering 3D printing technology. We are dedicated to revolutionizing the development and manufacturing of pharmaceutical products and unlocking the next generation of medicines through the use of 3D printing technology. Our state-of-the-art technology, called Melt-Extrusion Deposition (MED®), allows us to develop medicines in a layered construction to enable controlled and precise release of treatments. Our 3D printing technology platform encompasses dosage form design, digital pharmaceutical product development, and intelligent manufacturing.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Senping Cheng
Browse more venture capital transactions:
Prev: 9/28/2023: Maison Sport venture capital transaction
Next: 9/28/2023: Laverock Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs